Camrelizumab plus famitinib in patients with advanced or metastatic kidney cancer

An ongoing phase 2 study of a combination of two new medicines, camrelizumab (an immune checkpoint inhibitor) and famitinib (a novel tyrosine kinase inhibitor that targets a number of kinases) is looking at the safety and effectiveness of this combination in people with advanced or metastatic clear cell renal cell carcinoma (RCC). Previously treated people […]

read more
Showing the single result